Get the Stockscreener App
69.20
0.46%
0.32
Tarsus Pharmaceuticals Inc stock is traded at $69.20, with a volume of 448.24K.
It is up +0.46% in the last 24 hours and up +23.33% over the past month.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. TP-04 for the potential treatment of ocular rosacea and TP-05 for potential Lyme disease prophylaxis and community malaria reduction.
See More
Previous Close:
$68.88
Open:
$68.82
24h Volume:
448.24K
Relative Volume:
0.47
Market Cap:
$3.04B
Revenue:
$535.08M
Net Income/Loss:
$-48.27M
P/E Ratio:
-61.05
EPS:
-1.1335
Net Cash Flow:
$-31.54M
1W Performance:
+6.81%
1M Performance:
+23.33%
6M Performance:
+13.85%
1Y Performance:
+27.82%
1-Day Range:
$67.61
$69.70
1-Week Range:
$62.85
$71.34
52-Week Range:
$48.20
$85.25
Tarsus Pharmaceuticals Inc Stock (TARS) Company Profile
Name
Tarsus Pharmaceuticals Inc
Sector
Industry
Phone
(949) 409-9820
Address
15440 LAGUNA CANYON ROAD, IRVINE
Compare TARS vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TARS
Tarsus Pharmaceuticals Inc
|
69.20 | 3.07B | 535.08M | -48.27M | -31.54M | -1.1335 |
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Tarsus Pharmaceuticals Inc Stock (TARS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-24-26 | Resumed | Oppenheimer | Outperform |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Nov-20-25 | Initiated | Mizuho | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-27-25 | Resumed | H.C. Wainwright | Buy |
| Nov-20-23 | Initiated | Goldman | Neutral |
| Jul-18-23 | Initiated | William Blair | Outperform |
| May-18-23 | Initiated | Guggenheim | Buy |
| Aug-01-22 | Initiated | Barclays | Overweight |
| Dec-21-21 | Initiated | H.C. Wainwright | Buy |
| Nov-23-21 | Initiated | Oppenheimer | Outperform |
| Nov-10-20 | Initiated | BofA Securities | Buy |
| Nov-10-20 | Initiated | Jefferies | Buy |
| Nov-10-20 | Initiated | Ladenburg Thalmann | Buy |
| Nov-10-20 | Initiated | Raymond James | Strong Buy |
View All
Tarsus Pharmaceuticals Inc Stock (TARS) Latest News
Midday Stock Roundup: Mobix Labs Shares Fall 21% at Midday - Orange County Business Journal
Tarsus Pharmaceuticals (TARS) Stock Looks Reasonable On Sales While Earnings Stay Weak - Yahoo Finance
William Blair Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating - Moomoo
Janus Henderson Group Ltd. (TARS) discloses 6.5% beneficial stake in Tarsus - Stock Titan
Wasatch Advisors LP Buys New Holdings in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
How (TARS) Movements Inform Risk Allocation Models - Stock Traders Daily
Mizuho Securities Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $100 - Moomoo
TARS Maintained by Oppenheimer -- Price Target Raised to $100 - GuruFocus
Oppenheimer Adjusts PT on Tarsus Pharmaceuticals to $100 From $97, Keeps Outperform Rating - marketscreener.com
TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme - Stocktwits
Tarsus Pharmaceuticals Signs Agreement to Acquire Alkeus Pharmaceuticals - Global Legal Chronicle
The Manufacturers Life Insurance Company Cuts Stock Position in Tarsus Pharmaceuticals, Inc. $TARS - MarketBeat
Tarsus Pharmaceuticals, Inc. $TARS Shares Acquired by Bank of America Corp DE - MarketBeat
Why Tarsus Pharmaceuticals (TARS) Is Up 9.7% After Raising XDEMVY 2026 Sales Guidance And Acquiring Alkeus - Sahm
LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $104 - Moomoo
Tarsus Pharmaceuticals, Inc. $TARS Shares Sold by Assenagon Asset Management S.A. - MarketBeat
Tarsus Pharmaceuticals (NASDAQ:TARS) Issues Earnings Results - MarketBeat
Deal Watch: Tarsus Seeks Another Ophthalmology Buy With Alkeus Takeout Bid - insights.citeline.com
Tarsus Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
H.C. Wainwright Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Maintains Target Price $88 - Moomoo
LifeSci Capital Maintains Tarsus Pharmaceuticals(TARS.US) With Buy Rating, Raises Target Price to $104 - Moomoo
Mizuho Adjusts Tarsus Pharmaceuticals PT to $100 From $98, Maintains Outperform Rating - marketscreener.com
Tarsus joins Stargardt race to market with $800m Alkeus takeover - Yahoo Finance
Tarsus to acquire Alkeus for $450M upfront plus milestones By Investing.com - Investing.com South Africa
Tarsus to Acquire Alkeus in $450 Million Deal, Reports Strong Quarter and Half - VisionMonday.com
Latham & Watkins Advises Alkeus Pharmaceuticals on Acquisition by Tarsus Pharmaceuticals - Latham & Watkins LLP
Tarsus Bets Up To $800M On Alkeus In Retina Therapy Push - Law360
Tarsus Pharmaceuticals, Inc. Stock 12‑Month Price Target Cut to $93.57, Implies 53% Upside - TradingView
Tarsus Pharmaceuticals Inc (TARS) (Q2 2026) Earnings Call Highli - GuruFocus
Tarsus to purchase Alkeus Pharmaceuticals - Glance by Eyes On Eyecare
Alkeus, an unorthodox eye drug startup, acquired by Tarsus for up to $800M - BioPharma Dive
Tarsus Pharmaceuticals, Inc. entered into a definitive agreement to acquire Alkeus Pharmaceuticals, Inc. for approximately $800 million. - marketscreener.com
Tarsus Pharmaceuticals Inc (TARS) (Q2 2026) Earnings Call Highlights: Record XDEMVY Sales and ... - Yahoo Finance
Tarsus Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:TARS) 2026-08-06 - Seeking Alpha
Tarsus Pharmaceuticals Releases Q2 2026 Financial Results - AlphaStreet
Tarsus Pharmaceuticals Raises 2026 XDEMVY Net Pdt Sales Guidance to $685M-$705M >TARS - Moomoo
Tarsus Pharmaceuticals, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Is Tarsus Pharmaceuticals (TARS) Positioned for Growth After Q2 - GuruFocus
Tarsus Pharmaceuticals, Inc. - Reuters
Tarsus Pharmaceuticals posts Q2 XDEMVY sales of $173.9 million By Investing.com - Investing.com Nigeria
TARS Looks 71.0% Undervalued on GF Value™ but Faces Price-to-Sal - GuruFocus
Tarsus Pharmaceuticals raises $125 million in PIPE financing - Investing.com
Tarsus bets $450M on Alkeus’ Stargardt drug - Endpoints News
Tarsus Pharmaceuticals posts Q2 XDEMVY sales of $173.9 million - Investing.com
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Finance
Tarsus Pharmaceuticals Q2 sales beat estimates, lifts 2026 XDEMVY sales outlook - TradingView
Tarsus Pharmaceuticals (TARS) boosts H1 2026 revenue and turns operating cash flow positive - Stock Titan
Tarsus Pharmaceuticals raises $125 million in PIPE financing By Investing.com - Investing.com Nigeria
Tarsus Reports Second Quarter 2026 Financial Results, Advances Next Phase of Growth - GlobeNewswire
Tarsus to Raise About $125M, Selling Stock at $56 a Share - Stock Titan
Tarsus Pharmaceuticals to Acquire Alkeus Pharmaceuticals and Advance Eye Care Leadership Position - GlobeNewswire
Tarsus Pharmaceuticals Inc Stock (TARS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.52%
0.07%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):